GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Debt-to-Asset

Hubei Biocause Pharmaceutical Co (SZSE:000627) Debt-to-Asset : 0.08 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Debt-to-Asset?

Hubei Biocause Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥16,588 Mil. Hubei Biocause Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7,260 Mil. Hubei Biocause Pharmaceutical Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥282,374 Mil. Hubei Biocause Pharmaceutical Co's debt to asset for the quarter that ended in Mar. 2024 was 0.08.


Hubei Biocause Pharmaceutical Co Debt-to-Asset Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Debt-to-Asset Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.06 0.10 0.08

Hubei Biocause Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.08 0.08 0.08

Competitive Comparison of Hubei Biocause Pharmaceutical Co's Debt-to-Asset

For the Insurance - Life subindustry, Hubei Biocause Pharmaceutical Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hubei Biocause Pharmaceutical Co's Debt-to-Asset Distribution in the Insurance Industry

For the Insurance industry and Financial Services sector, Hubei Biocause Pharmaceutical Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Hubei Biocause Pharmaceutical Co's Debt-to-Asset falls into.



Hubei Biocause Pharmaceutical Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Hubei Biocause Pharmaceutical Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(18248.1 + 7170.777) / 301935.93
=0.08

Hubei Biocause Pharmaceutical Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(16587.83 + 7259.731) / 282374.342
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hubei Biocause Pharmaceutical Co  (SZSE:000627) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Hubei Biocause Pharmaceutical Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Executives
Jiang Hai Hua Independent director
Fu Yong Jin Directors, executives
Wu Shi Yan Supervisors

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines